Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05446870
Title	Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Recruitment	Completed
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	ovarian serous carcinoma peritoneum cancer fallopian tube cancer
Therapies	Bevacizumab + Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| POL \| ITA \| ISR \| ESP \| CAN \| BEL